

Meeting title:	Public Trust Board				
Date of the meeting:	12 December 2024				
Title:	Summary from UHL/UHN Partnership Committee				
Report presented by:	Becky Cassidy, Director of Corporate & Legal Affairs				
Report written by:	Becky Cassidy, Director of Corporate & Legal Affairs				
Action – this paper is for:	Decision/Approval		Assurance	x	Update
Where this report has been discussed previously	Not applicable				

1. **Purpose of the Report**

To provide the UHL Trust Board with a summary of the discussions from the recent Partnership Committee which took place on 1 November 2024. There are no formal escalations to bring to the attention of the Trust Board.

2. **Recommendation**

To Trust Board are asked to receive the highlight update and specifically note the ongoing progress of the agreed workstreams within the collaboration, and that there is an agreed scope and approach to the development of a group clinical strategy.

3. **Summary**

Collaboration programme

An overview of the collaboration progress was presented and discussed. The key highlight areas were:

- The appointment of a Joint Associate Director for Research and Innovation.
- Transfer of approximately 270 patients across the three Trusts.
- Agreement on approaches for developing clinical and digital strategies.
- Shared learning across various areas.
- Increased collaboration among teams, although operational pressures at both hospitals had slowed progress.

Each workstream has identified the benefits that they are anticipating to be developed through this work across four categories of benefits with a balance between quality, risk reduction, people and finance. KPI benefits are being tracked and oversight will continue through the Partnership Committee.

An update on the improving waiting times workstream, which had progressed well, emphasised improvements in waiting times and mutual aid between the three Trusts. The committee was informed that the Federated Data Platform would provide a shared waiting list. The importance of breaking down silos and presenting a unified vision for collaboration was emphasised.

It was agreed that each workstream should clearly outline its intended outcomes and the overall role it played, to help break down silos and ensure effective communication aligning everyone around a shared vision and timeline for execution.

Development of clinical services strategy

The scope of the Group Clinical Strategy had been discussed and supported by the Joint Executive team. A written strategy would be produced with input from both UHL and UHN colleagues by Spring 2025 for approval by the Partnership Committee and trusts' Boards. The strategy will describe our plans for integrated care and is the nucleus of our organisational strategies.

The committee discussed the approach to the development of the strategy and highlighted the following key points:

- The need to engage meaningfully with patients, colleagues and education centres who were training staff, to inform the strategy.
- The importance of explaining to colleagues why the strategy was being developed as a Group and how the strategy would benefit colleagues and patients.
- The importance of clear communication and the need for a stakeholder map was highlighted. A stakeholder map would be produced.

The committee approved the approach to the development of the Group Clinical Strategy. The involvement of the UHL and UHN Board and internal colleagues will be fully engaged throughout the development of the strategy.